Sigumir
A Khavinson-class ultrashort tetrapeptide bioregulator investigated for joint, cartilage, and connective tissue support.
Sigumir is a short peptide bioregulator (Val-Glu-Pro-Arg) developed within the Khavinson research tradition and proposed to target articular cartilage, bone, and connective tissue. It is thought to reach musculoskeletal tissues via amino acid transporter mechanisms and to modulate gene expression in aging musculoskeletal cells. Human clinical data specific to sigumir is sparse, and current evidence rests on class-level mechanistic and preclinical research rather than direct sigumir trials.
Class
Synthetic tetrapeptide bioregulator (Khavinson class)
Half-life
Unknown
Routes
Subcutaneous, Oral, Sublingual
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Joint tissue repair
Sigumir is proposed to support repair of joint tissue by modulating osteoblast and chondrocyte activity. Evidence is preclinical and class-level rather than from direct sigumir trials.
Bone and cartilage support
As a bioregulator targeting the musculoskeletal system, sigumir is investigated for promoting extracellular matrix production in cartilage and bone tissue.
Anti-inflammatory (joint)
The peptide is proposed to reduce local joint inflammation, which may contribute to its investigated role in connective tissue support.
Mobility improvement
Through its proposed effects on cartilage integrity and joint inflammation, sigumir is studied as a research tool for supporting joint mobility in aging musculoskeletal cells.
Mechanism
How it works
Sigumir is a Khavinson-class ultrashort peptide (Val-Glu-Pro-Arg) proposed to act as a tissue-specific bioregulator for joint and bone tissue. Its mechanism is described as modulating osteoblast and chondrocyte activity, reducing local joint inflammation, and promoting extracellular matrix production in connective tissue.
Like other peptides in this class, sigumir is proposed to reach musculoskeletal target tissues via amino acid transporter mechanisms. Computational molecular modeling and docking work on 26 ultrashort bioactive peptides, including sigumir, found systematically higher binding scores to LAT1, LAT2, and PEPT1 transporters compared with non-bioactive controls, supporting efficient cellular uptake as a route into target cells.
Once inside cells, short peptides of this class are proposed to regulate gene expression through chromatin binding and selective gene modulation. A systematic review of peptide regulation of gene expression documents these properties for short peptides including sigumir, providing mechanistic context for its proposed cartilage- and joint-protective activity.
Sigumir's proposed target of articular cartilage and connective tissue distinguishes it from other Khavinson peptides that target specific organ systems (for example Testagen for testicular tissue or Thymalin for thymic tissue). Human clinical data specific to sigumir is sparse; the mechanistic case is built on class-level and preclinical research rather than direct sigumir-specific trials.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Research (oral/sublingual)
- Dose
- No validated dose established
- Frequency
- Intermittent cycles
- Timing
- Per Khavinson cycling tradition
- Duration
- Cyclical (typical bioregulator courses)
- Route
- Oral capsule or sublingual
Sigumir is typically formulated as an oral capsule or sublingual peptide bioregulator and studied in intermittent cycles consistent with the gene-expression modulation mechanism proposed for the class. No validated human dosing regimen and no dose-ranging human clinical trial has been conducted for this compound.
- No validated human dosing regimen has been established for sigumir; there is no published dose-ranging human trial.
- Sigumir is studied in intermittent cycles rather than continuous daily use, consistent with the gene-expression modulation mechanism proposed for Khavinson-class peptides.
- It is most commonly formulated as an oral capsule or sublingual product in the Khavinson research tradition.
Evidence
Research & clinical studies (2)
Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters
This computational molecular modeling and docking study found that 26 ultrashort bioactive peptides including sigumir show systematically higher binding scores to LAT1, LAT2, and PEPT1 transporters than non-bioactive controls, supporting efficient cellular uptake as a mechanism for this class of short cartilage-regulatory peptides.
PMID 36979488Peptide Regulation of Gene Expression: A Systematic Review
This systematic review documents the gene expression regulatory properties of short peptides including sigumir, showing chromatin binding and selective gene modulation in target connective tissue cells and providing mechanistic context for cartilage and joint tissue-protective activity.
PMID 34834147Safety
Side effects & considerations
Sigumir is generally considered lower risk in research contexts, with no established contraindications reported in available sources. Individual response varies, and human safety data specific to sigumir is limited. Consult a qualified healthcare professional before use.
FAQ
Sigumir — common questions
What is Sigumir?
Sigumir is a Khavinson-class short bioregulator peptide (Val-Glu-Pro-Arg) investigated for joint, cartilage, and connective tissue support. Like other ultrashort peptides in this category, it is proposed to reach musculoskeletal target tissues via amino acid transporter mechanisms and modulate gene expression in aging musculoskeletal cells.
What is Sigumir primarily studied for?
Sigumir is primarily studied for joint tissue repair, bone and cartilage support, anti-inflammatory effects in the joint, and mobility improvement.
What are the reported benefits of Sigumir?
Research on sigumir primarily documents effects related to joint tissue repair, bone and cartilage support, anti-inflammatory activity in the joint, and mobility improvement. These are areas covered in preclinical and class-level literature; individual response varies and effects depend on context of use.
What are the side effects of Sigumir?
No contraindications or specific side effects are established in the available sources. Sigumir is considered lower risk in research contexts, but human safety data is limited, so consult a qualified healthcare professional before use.
How is Sigumir taken?
Sigumir is typically formulated as an oral capsule or sublingual peptide bioregulator and studied in intermittent cycles. No validated human dosing regimen has been established for the compound.
What does the research show about Sigumir?
A computational molecular modeling and docking study found that ultrashort bioactive peptides including sigumir bind LAT1, LAT2, and PEPT1 transporters more strongly than non-bioactive controls, supporting efficient cellular uptake as a mechanism. A systematic review further documents gene expression regulatory properties of short peptides including sigumir.
Is Sigumir FDA-approved?
No. Sigumir is a Russian joint peptide bioregulator from the Khavinson Institute. It is not FDA-approved, appears on no FDA list, and is treated as a research chemical in the US.
